Crown Laboratories and Revance Amend the A&R Merger Agreement to Increase Offer Price to $3.65 per Share and Extend Existing Tender Offer

Increased offer price to $3.65 per share, a$0.55 per share increase Improved offer unanimously approved by Revance Board of Directors Crown to extend tender offer until 11:59 p.m., Eastern Time, on February 4, 2025 Crown's offer is the only fully-financed offer currently available to Revance's stockholders Outside termination date under the A&R Merger Agreement is February 7, 2025 JOHNSON CITY, Tenn. and NASHVILLE, Tenn., Jan. 21, 2025 /PRNewswire/ -- Crown Laboratories, Inc. ("Crown") and Revance Therape ...